Chronic Pain – Pipeline Review, H2 2016
Global Markets Direct’s, ‘Chronic Pain – Pipeline Review, H2 2016’, provides an overview of the Chronic Pain pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real-time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios enhance decision-making capabilities and help to create effective counter-strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Chronic Pain
The report reviews pipeline therapeutics for Chronic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Chronic Pain therapeutics and enlist all their major and minor projects
The report assesses Chronic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews the latest news related to pipeline therapeutics for Chronic Pain
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with the potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage
Identify and understand important and diverse types of therapeutics under development for Chronic Pain
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
AbbVie Inc
Acadia Pharmaceuticals Inc.
Adynxx, Inc.
Allergan Plc
Amorsa Therapeutics Inc.
arGEN-X BV
Asana BioSciences, LLC
AskAt Inc.
Astraea Therapeutics, LLC
Axsome Therapeutics, Inc.
BioDelivery Sciences International, Inc.
Biogen Inc
Bionomics Limited
Camurus AB
Cara Therapeutics, Inc.
Centrexion Therapeutics Corp
ChironWells GmbH
Collegium Pharmaceutical, Inc.
Crinetics Pharmaceuticals, Inc.
Cyclenium Pharma, Inc.
Cytogel Pharma, LLC
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Dompe Farmaceutici S.p.A.
Echo Pharmaceuticals B.V.
Egalet Corporation
Eli Lilly and Company
Elite Pharmaceuticals, Inc.
Glenmark Pharmaceuticals Ltd.
Grunenthal GmbH
Heron Therapeutics, Inc.
INSYS Therapeutics, Inc.
Johnson & Johnson
Kareus Therapeutics, SA
KPI Therapeutics, Inc.
Kymab Limited
Laboratorios Del Dr. Esteve S.A.
Lohocla Research Corporation
Lpath, Inc.
MD Biosciences GmbH
Merck & Co., Inc.
Moberg Pharma AB
Mundipharma International Ltd
Nanomerics Ltd
Nektar Therapeutics
Neura Therapeutik, LLC
Orion Oyj
Pacira Pharmaceuticals, Inc.
Pain Therapeutics, Inc.
PeriphaGen, Inc.
Pfizer Inc.
Phosphagenics Limited
Prismic Pharmaceuticals, Inc.
Purdue Pharma LP
Relmada Therapeutics, Inc.
Ribomic Inc.
Sea4Us
Shulov Innovative Science Ltd.
Synactix Pharmaceuticals, Inc.
Syntrix Biosystems, Inc.
Teva Pharmaceutical Industries Ltd.
Therapix Biosciences Ltd.
Trevena, Inc.
Voyager Therapeutics, Inc.
Yooyoung Pharmaceutical Co., Ltd.
Zynerba Pharmaceuticals, Inc.
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Chronic Pain Overview 12
Therapeutics Development 13
Pipeline Products for Chronic Pain - Overview 13
Pipeline Products for Chronic Pain - Comparative Analysis 14
Chronic Pain - Therapeutics under Development by Companies 15
Chronic Pain - Therapeutics under Investigation by Universities/Institutes 22
Chronic Pain - Pipeline Products Glance 23
Late Stage Products 23
Clinical Stage Products 24
Early Stage Products 25
Unknown Stage Products 26
Chronic Pain - Products under Development by Companies 27
Chronic Pain - Products under Investigation by Universities/Institutes 35
Chronic Pain - Companies Involved in Therapeutics Development 36
AbbVie Inc 36
Acadia Pharmaceuticals Inc. 37
Adynxx, Inc. 38
Allergan Plc 39
Amorsa Therapeutics Inc. 40
arGEN-X BV 41
Asana BioSciences, LLC 42
AskAt Inc. 43
Astraea Therapeutics, LLC 44
Axsome Therapeutics, Inc. 45
BioDelivery Sciences International, Inc. 46
Biogen Inc 47
Bionomics Limited 48
Camurus AB 49
Cara Therapeutics, Inc. 50
Centrexion Therapeutics Corp 51
ChironWells GmbH 52
Collegium Pharmaceutical, Inc. 53
Crinetics Pharmaceuticals, Inc. 54
Cyclenium Pharma, Inc. 55
Cytogel Pharma, LLC 56
Daewoong Pharmaceutical Co., Ltd. 57
Daiichi Sankyo Company, Limited 58
Dompe Farmaceutici S.p.A. 59
Echo Pharmaceuticals B.V. 60
Egalet Corporation 61
Eli Lilly and Company 62
Elite Pharmaceuticals, Inc. 63
Glenmark Pharmaceuticals Ltd. 64
Grunenthal GmbH 65
Heron Therapeutics, Inc. 66
INSYS Therapeutics, Inc. 67
Johnson & Johnson 68
Kareus Therapeutics, SA 69
KPI Therapeutics, Inc. 70
Kymab Limited 71
Laboratorios Del Dr. Esteve S.A. 72
Lohocla Research Corporation 73
Lpath, Inc. 74
MD Biosciences GmbH 75
Merck & Co., Inc. 76
Moberg Pharma AB 77
Mundipharma International Ltd 78
Nanomerics Ltd 79
Nektar Therapeutics 80
Neura Therapeutik, LLC 81
Orion Oyj 82
Pacira Pharmaceuticals, Inc. 83
Pain Therapeutics, Inc. 84
PeriphaGen, Inc. 85
Pfizer Inc. 86
Phosphagenics Limited 87
Prismic Pharmaceuticals, Inc. 88
Purdue Pharma LP 89
Relmada Therapeutics, Inc. 90
Ribomic Inc. 91
Sea4Us 92
Shulov Innovative Science Ltd. 93
Synactix Pharmaceuticals, Inc. 94
Syntrix Biosystems, Inc. 95
Teva Pharmaceutical Industries Ltd. 96
Therapix Biosciences Ltd. 97
Trevena, Inc. 98
Voyager Therapeutics, Inc. 99
Yooyoung Pharmaceutical Co., Ltd. 100
Zynerba Pharmaceuticals, Inc. 101
Chronic Pain - Therapeutics Assessment 102
Assessment by Monotherapy Products 102
Assessment by Combination Products 103
Assessment by Target 104
Assessment by Mechanism of Action 111
Assessment by Route of Administration 118
Assessment by Molecule Type 120
Drug Profiles 122
(celecoxib + tramadol hydrochloride) - Drug Profile 122
(hydrocodone bitartrate + palmidrol) - Drug Profile 124
(morphine sulfate + palmidrol) - Drug Profile 125
(naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile 126
(oxycodone hydrochloride + palmidrol) - Drug Profile 127
(palmidrol + pregabalin) - Drug Profile 128
A-200 - Drug Profile 129
AGN-XX - Drug Profile 130
AGN-YY - Drug Profile 131
AMS-520 - Drug Profile 132
ASN-008 - Drug Profile 133
AVLX-144 - Drug Profile 134
AXS-06 - Drug Profile 135
AYX-1 - Drug Profile 136
AYX-2 - Drug Profile 138
BBI-11008 - Drug Profile 139
bupivacaine - Drug Profile 140
bupivacaine hydrochloride - Drug Profile 142
buprenorphine hydrochloride - Drug Profile 144
buprenorphine hydrochloride depot - Drug Profile 146
buprenorphine hydrochloride ER - Drug Profile 147
buprenorphine hydrochloride long acting - Drug Profile 149
cebranopadol - Drug Profile 150
cetirizine hydrochloride + cromolyn sodium - Drug Profile 153
cetuximab - Drug Profile 154
CNTX-0290 - Drug Profile 160
CNV-3000164 - Drug Profile 161
CNV-3000223 - Drug Profile 162
CR-4056 - Drug Profile 163
CR-701 - Drug Profile 164
CRB-0089 - Drug Profile 165
Cyt-1010 - Drug Profile 166
dexmedetomidine hydrochloride - Drug Profile 168
DF-2593A - Drug Profile 170
difelikefalin - Drug Profile 171
dronabinol - Drug Profile 178
DS-1971 - Drug Profile 180
DWJ-208 - Drug Profile 181
ECP-1014 - Drug Profile 182
Egalet-003 - Drug Profile 183
fluticasone propionate - Drug Profile 184
FY-101C - Drug Profile 185
FY-103B - Drug Profile 186
GBR-900 - Drug Profile 187
Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile 188
grapiprant - Drug Profile 189
HPI-201 - Drug Profile 191
HS-731 - Drug Profile 192
hydrocodone bitartrate ER - Drug Profile 193
hydrocodone bitartrate ER - Drug Profile 196
hydrocodone bitartrate ER - Drug Profile 197
hydromorphone hydrochloride - Drug Profile 198
Kindolor - Drug Profile 199
KY-1017 - Drug Profile 200
L-779976 - Drug Profile 201
lacosamide - Drug Profile 202
LEVI-04 - Drug Profile 203
levorphanol tartrate ER - Drug Profile 204
Lpathomab - Drug Profile 206
MD-354 - Drug Profile 209
Monoclonal Antibodies for Chronic Pain - Drug Profile 210
Monoclonal Antibodies to Block Nav1.7 for Chronic Pain - Drug Profile 211
morphine sulfate ER - Drug Profile 212
MR-309 - Drug Profile 216
NET-END - Drug Profile 218
NKTR-181 - Drug Profile 219
NL-001 - Drug Profile 222
NL-002 - Drug Profile 223
NM-0127 - Drug Profile 224
Omnitram - Drug Profile 225
onabotulinumtoxin A - Drug Profile 226
OSX-300 - Drug Profile 231
OSX-300 Backups - Drug Profile 232
oxycodone hydrochloride ER - Drug Profile 233
oxycodone hydrochloride ER - Drug Profile 236
oxycodone hydrochloride ER - Drug Profile 237
oxymorphone hydrochloride - Drug Profile 239
oxymorphone hydrochloride ER - Drug Profile 240
PAC-CP - Drug Profile 241
palmidrol - Drug Profile 242
Peptide to Block Cav2.2 for CNS Disorders - Drug Profile 243
Peptides to Inhibit Ion Channel for Chronic Pain - Drug Profile 244
Peptides to Target TRPV1 for Pain and Itch - Drug Profile 245
PN-6047 - Drug Profile 246
PRC-062 - Drug Profile 247
Prostatic Acid Phosphatase - Drug Profile 248
PspTx-3 - Drug Profile 249
raxatrigine hydrochloride - Drug Profile 250
RBM-005 - Drug Profile 253
REL-1017 - Drug Profile 254
SAFit2 - Drug Profile 257
Small Molecule for Chronic Pain - Drug Profile 258
Small Molecule for Chronic Pain - Drug Profile 259
Small Molecule for Neuropathic Pain, Chronic Pain and Inflammatory Pain - Drug Profile 260
Small Molecule to Antagonize GPR-84 for Chronic Pain - Drug Profile 261
Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile 262
Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile 264
Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile 265
Small Molecule to Inhibit mPGES-1 for Chronic Pain - Drug Profile 266
Small Molecules for Chronic Wound Pain - Drug Profile 267
Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder - Drug Profile 268
Small Molecules to Agonize Cannabinoid Type 1 and Type 2 Receptors for Chronic Pain and Neuropathic Pain - Drug Profile 269
Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile 270
Small Molecules to Agonize Delta Opioid Receptor for Chronic Pain - Drug Profile 271
Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile 272
Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile 273
Small Molecules to Agonize SSTR4 for Neuropathic Pain and Chronic Pain - Drug Profile 274
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 275
Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 276
Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 277
Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain - Drug Profile 278
Small Molecules to Block Nav
1.7 Channels for Chronic And Neuropathic Pain - Drug Profile 279
Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile 280
Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain - Drug Profile 281
Small Molecules to Inhibit Cyclooxygenase 2 for Chronic Pain - Drug Profile 282
Small Molecules to Inhibit DAAO for Chronic Pain - Drug Profile 283
Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain - Drug Profile 284
Small Molecules to Target Opioid Receptors for Chronic Pain - Drug Profile 285
SYN-003 - Drug Profile 286
Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain - Drug Profile 287
tanezumab - Drug Profile 288
tapentadol hydrochloride IR - Drug Profile 291
TRV-734 - Drug Profile 293
U-2902 - Drug Profile 295
UMB-425 - Drug Profile 297
Vaccine to Target MCP-1 for Chronic Prostatitis and Chronic Pelvic Pain - Drug Profile 298
VM-902A - Drug Profile 299
VYNAV-01 - Drug Profile 300
XT-101 - Drug Profile 301
YYC-301 - Drug Profile 302
ZEP-3 - Drug Profile 303
ZYN-001 - Drug Profile 304
Chronic Pain - Dormant Projects 305
Chronic Pain - Discontinued Products 314
Chronic Pain - Product Development Milestones 317
Featured News & Press Releases 317
Appendix 325
Methodology 325
Coverage 325
Secondary Research 325
Primary Research 325
Expert Panel Validation 325
Contact Us 325
Disclaimer 326
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets